{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AVTX",
  "name": "Avalo Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/AVTX/",
  "json_url": "https://orbyd.app/dossiers/AVTX.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Post-LOTUS de-risked anti–IL-1β (abdakibart) story: funded into 2029, Russell-included, sell-side $35–38, but digesting ~21% off the $24.27 high — MATURING, not accelerating. The 2026-07-30 Q2 call (Phase 3 design/BD tone, this week) is a soft catalyst carrying event risk into a thin float; no breakout structure to chase here, so stand aside for a base-hold.",
  "invalidation_trigger": "A weekly close below $16 breaks the post-LOTUS consolidation base and signals the re-rate is unwinding; secondary confirmation if the 2026-07-30 call slips Phase 3 timing or the precision-biotech theme flips to SATURATED as sell-side marks targets lower.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Theme read is MATURING, not ACCELERATING — coverage/index news is post-move confirmation; buy base-holds/re-acceleration, avoid chasing the May spike.",
    "Primary binary already resolved: LOTUS Phase 2 positive 2026-05-05 (HiSCR75 Wk16 42.2%/42.9% vs 25.6% placebo, >250 pts). Next hard clinical catalyst is Phase 3 topline, years out.",
    "Next dated event 2026-07-30 (Q2 2026 call) — soft catalyst; watch Phase 3 design/timing + BD tone, not a binary readout. As of 2026-07-26 the call is ~4 trading days out — event risk into a thin float.",
    "Balance sheet: ~$431M raise (May 2026), cash into 2029 for operations — additional financing expected to fully fund Phase 3 (dilution risk returns once costed).",
    "Russell 2000/3000 inclusion effective 2026-06-26 added a passive bid; thin 52.6M-share float, high volatility.",
    "Sell-side cluster: B of A Buy $35 (2026-06-12), Leerink Outperform $38 (2026-07-06); consensus avg ~$44, range $24-$62.",
    "AVTX-010 next-gen long-acting anti-IL-1β IND planned H1 2027 (announced 2026-06-16) — franchise optionality, not a near-term driver.",
    "Name read is MATURING/digesting even as the precision-biotech-therapeutics cohort was tagged ACCELERATING 2026-07-20; buy base-holds/re-acceleration, avoid chasing the May spike or the pause below the $24.27 high."
  ],
  "body_markdown": "## Current Thesis\nThe binary that defined this name has already fired. On 2026-05-05 Avalo's Phase 2 LOTUS trial of abdakibart (AVTX-009), a high-affinity anti–IL-1β monoclonal antibody, hit its primary endpoint in moderate-to-severe hidradenitis suppurativa (HS): HiSCR75 at Week 16 of 42.2% (150mg) and 42.9% (300mg) against 25.6% placebo across >250 patients. That print re-rated the stock roughly 4x off its $4.61 52-week low and pulled the company into registrational Phase 3 planning. What trades today is the aftermath leg — a fully funded (cash into 2029 after a ~$431M May raise), Russell-included, sell-side-endorsed single-asset immunology story consolidating below its high. Last quoted near $19.21 (close 2026-07-10), the stock sits ~21% under its $24.27 high with the slope flattening: a digesting continuation rather than an accelerating breakout. The precision-biotech-therapeutics cohort was tagged ACCELERATING on 2026-07-20, but this specific name has not re-accelerated with it. The next dated read is the 2026-07-30 Q2 call — this week — for Phase 3 design, timing, and BD tone; a soft catalyst that still carries event risk into a thin float. The disciplined stance is to let the print pass and buy a confirmed base-hold or re-acceleration rather than chase a pause below the high.\n\n## Bull Case\n- **De-risked lead asset.** LOTUS met HiSCR75 — a demanding bar, since most HS trials headline HiSCR50 — at both doses with ~17pt placebo separation, reported 2026-05-05. Efficacy is clinical fact now.\n- **Balance sheet removes the small-cap trap.** A ~$431.3M offering (May 2026) funds operations into 2029, clearing near-term dilution overhang through Phase 3 initiation.\n- **Coverage cluster off the data.** B of A Buy $35 (2026-06-12) and Leerink Outperform $38 (2026-07-06); consensus averages near $44 against a ~$19 quote, range $24–$62.\n- **Passive bid installed.** Russell 2000/3000 inclusion effective 2026-06-26 broadened the holder base and improved liquidity in a 52.6M-share float.\n- **M&A optionality.** A cash-rich, de-risked anti–IL-1β asset in a $10B+ immuno-dermatology TAM is a credible takeout; buyout scenarios featured across June 2026 notes.\n- **Franchise depth.** AVTX-010, a long-acting next-gen anti–IL-1β mAb with IND planned H1 2027 (announced 2026-06-16), extends the mechanism beyond HS.\n- **Sector tailwind.** The precision-biotech-therapeutics theme was flagged ACCELERATING on 2026-07-20 — peer breakouts would confirm small-cap biotech risk appetite.\n\n## Bear Case\n- **The catalyst is spent.** The LOTUS move (2026-05-05) is behind the tape; the next hard clinical readout is Phase 3 topline, years out. Initiations and index inclusion are backward-looking.\n- **Good, not dominant.** 42% HiSCR75 against a high 25.6% placebo rate must replicate in Phase 3 and will be benchmarked against Novartis' Cosentyx (FDA-approved in HS since October 2023) and UCB's Bimzelx.\n- **Dilution returns.** Despite the \"into 2029\" opex runway, additional financing is expected specifically to fund a full Phase 3 — the raise clock resets once the program is costed.\n- **Most de-risking is priced.** At ~$1.0B market cap on one Phase 2 asset, the easy 4x re-rate off the $4.61 low has happened while approval and execution risk remain.\n- **Tape has cooled.** ~21% off the $24.27 high and digesting below it as of the 2026-07-10 quote near $19.21 — momentum is decelerating.\n- **Event risk without payoff.** The 2026-07-30 Q2 call can gap a thin float on Phase 3 or financing commentary without offering a binary upside catalyst.\n\n## Setup & Price Structure\n- Last quoted near $19.21 (close 2026-07-10); ~21% under the $24.27 high; slope flattening. Market cap ~$1.0B, 52.6M shares outstanding, Nasdaq Capital Market.\n- 52-week range $4.61–$24.27. The post-LOTUS consolidation base sits above ~$16; that shelf is the structural line for the re-rate.\n- Thin 52.6M float plus the Russell passive bid (effective 2026-06-26) makes for high volatility and two-way gaps around dated events.\n- No accelerating breakout structure is present — the pattern is post-catalyst digestion, so a fresh entry at current levels buys the pause; the cleaner setup is a base-hold reclaim of the $24.27 high on expanding volume.\n\n## Catalyst Calendar (next 30 days)\n\n- **~H2 2026 (est.) — Phase 3 initiation guidance.** Registrational design and start-date detail; the 7/30 call should refine this.\n- **Distant (years out) — Phase 3 topline.** The next true binary readout; no interim clinical data expected inside 30 days.\n\n## Elapsed catalysts\n\n- **2026-07-30 — Q2 2026 earnings call.** Watch Phase 3 design, initiation timing, BD/partnership tone, and any financing signaling. Soft catalyst; primary near-term event, ~4 trading days out. *(passed 10d ago)*\n- **H1 2027 (est.) — AVTX-010 IND filing** (plan announced 2026-06-16). Franchise-extension milestone, not a near-term driver. *(passed 54d ago)*\n\n## What Would Change Our Mind\n- **Bull confirmation:** a weekly close back above the $24.27 high on expanding volume, alongside precision-biotech peer breakouts, would re-open the accelerating case and argue the digestion is complete.\n- **Bear confirmation:** a weekly close below $16 breaks the post-LOTUS consolidation base and signals the re-rate is unwinding.\n- **Event risk at the print:** Phase 3 timing that slips, a design that reads underpowered, or fresh financing that reintroduces dilution at the 2026-07-30 call.\n- **Theme decay:** the precision-biotech cohort flipping to SATURATED as sell-side marks targets lower.\n\n## Correlation Notes\n- Idiosyncratic single-asset clinical biotech: price is driven by AVTX-009 trial and regulatory events, not index beta, but sentiment tracks small-cap biotech risk appetite (XBI/IBB) and long-duration rate moves that discount distant cash flows.\n- HS-space read-throughs matter: competitive data from Cosentyx (Novartis) and Bimzelx (UCB), plus Humira biosimilar dynamics, reset the efficacy benchmark abdakibart is measured against.\n- Russell 2000/3000 membership (effective 2026-06-26) ties the name to small-cap passive flows and IWM rebalance mechanics in a thin float.\n- Precision-biotech-therapeutics cohort (tagged 2026-07-20, ACCELERATING): peer breakouts confirm or deny the sector tailwind this name would need to re-accelerate.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T11:51:58+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}